Search Result

Results for "

Colorectal carcinomas

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADC Payload (1) Akt (7) AMPK (1) Amyloid-β (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (47) Aryl Hydrocarbon Receptor (1) Asialoglycoprotein Receptor (ASGPR) (1) ATM/ATR (2) Autophagy (10) Bacterial (1) Bcl-2 Family (8) Biochemical Assay Reagents (5) c-Myc (2) Cadherin (4) Calcium Channel (1) Carbonic Anhydrase (1) Carboxylesterase (CES) (1) Caspase (14) CCR (1) CD3 (1) CD47 (1) CDK (5) CMV (1) COX (1) CXCR (1) Cytochrome P450 (3) Deubiquitinase (3) Dihydrofolate reductase (DHFR) (1) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (10) Drug Derivative (3) Drug Isomer (1) Drug Metabolite (2) Drug-Linker Conjugates for ADC (2) E-Selectin (1) E1/E2/E3 Enzyme (2) EGFR (11) Endogenous Metabolite (8) Epigenetic Reader Domain (2) ERK (4) FABP (1) FAK (1) Ferroptosis (3) FGFR (2) FLT3 (2) Folate Receptor (FR) (1) Free Fatty Acid Receptor (1) FXR (1) GABA Receptor (1) Glucosylceramide Synthase (GCS) (1) GLUT (1) Glutathione Peroxidase (1) HDAC (3) Histone Demethylase (5) Histone Methyltransferase (3) HSP (1) HSV (1) IAP (1) IFNAR (2) IKK (2) Integrin (1) Interleukin Related (4) Isotope-Labeled Compounds (4) JNK (3) MDM-2/p53 (3) MEK (3) Methionine Adenosyltransferase (MAT) (1) METTL3 (1) MHC (2) Microtubule/Tubulin (5) Mitochondrial Metabolism (4) Mitosis (1) MMP (4) MOFs (1) Mps1 (1) mTOR (4) Mucin (1) NAMPT (1) Necroptosis (1) NEKs (1) NF-κB (4) Nuclear Factor of activated T Cells (NFAT) (1) Nucleoside Antimetabolite/Analog (1) P-glycoprotein (2) p38 MAPK (6) PARP (5) PASK/STK37 (1) PD-1/PD-L1 (2) Peptide-Drug Conjugates (PDCs) (2) PERK (2) Phosphatase (1) PI3K (3) Polo-like Kinase (PLK) (1) Pregnane X Receptor (PXR) (1) PROTACs (2) Pyroptosis (2) Raf (5) Ras (3) Reactive Oxygen Species (ROS) (6) Reference Standards (4) ROCK (1) SARS-CoV (1) Scavenger Receptor Class B type I (SR-BI） (1) SOD (2) SOS1 (1) STAT (5) STING (3) Succinate Receptor 1 (1) Survivin (2) TGF-beta/Smad (3) TGF-β Receptor (2) TNF Receptor (3) Toll-like Receptor (TLR) (2) Topoisomerase (5) Transmembrane Glycoprotein (4) Trk Receptor (2) TRP Channel (1) Tyrosinase (1) ULK (1) VEGFR (8) Wee1 (1) Wnt (1) YAP (1)
By Research Areas:	Cancer (146) Cardiovascular Disease (4) Endocrinology (1) Infection (6) Inflammation/Immunology (15) Metabolic Disease (5) Neurological Disease (6)
Oligonucleotides:	Polymers (1)

145

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13653

(-)-Epigallocatechin Gallate Maximum Cited Publications 57 Publications Verification EGCG; Epigallocatechol Gallate	Endogenous Metabolite Apoptosis	Inflammation/Immunology Cancer
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-13902

Berzosertib 20+ Cited Publications VE-822; VX-970; M6620	ATM/ATR Apoptosis STING Caspase	Infection Metabolic Disease Cancer
Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G₂/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-148807

Zavondemstat QC8222 free base; TACH 101 free base	Histone Demethylase Apoptosis	Cancer
Zavondemstat (QC8222 free base; TACH 101 free base) is an orally active pan-KDM4 inhibitor, with a IC₅₀ ≤ 0.08 μM against human KDM4A-D and a Kᵢ of 0.52 μM against human KDM4C. Zavondemstat induces cell apoptosis, causes S-phase cell cycle arrest, reduces the population of tumor-initiating cells and inhibits cancer cell proliferation. Zavondemstat suppresses tumor growth and induces tumor regression in mouse xenograft models. Zavondemstat can be used for the research of various cancers including colorectal cancer, esophageal squamous cell carcinoma and triple-negative breast cancer .

HY-150190

F5446 1 Publications Verification	Histone Methyltransferase Apoptosis	Cancer
F5446 (Compound 1) is a selective small molecule inhibitor of SUV39H1 methyltransferase. F5446 decreases H3K9me3 deposition at the FAS promoter, increases Fas expression and increases colorectal carcinoma cell sensitivity to FasL-induced apoptosis in vitro. F5446 suppresses human colon tumor xenograft growth in vivo .

HY-W008091

5-Methylcytosine 2 Publications Verification	DNA/RNA Synthesis Endogenous Metabolite	Cancer
5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma .

HY-P990957

Ficerafusp alfa BCA-101; FMAB2	EGFR TGF-beta/Smad	Inflammation/Immunology Cancer
Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a K_d of 2.58 nM against EGFR and a K_d of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatory T cells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .

HY-137465

CG428	PROTACs Trk Receptor	Cancer
CG428 is a potent and selective CRBN-dependent tropomyosin receptor kinase (TRK) PROTAC degrader that has anti-tumor activity. CG428 reduces levels of the tropomyosin 3 TPM3-TRKA fusion protein in KM12 colorectal carcinoma cells (DC₅₀ = 0.36 nM) and inhibits downstream PLCγ1 phosphorylation (IC₅₀ = 0.33 nM). CG428 has a higher binding affinity for TRKA than TRKB and TRKC (Kd = 1 nM, 28 nM and 4.2 nM, respectively). CG428 can be used for the research of colorectal carcinoma .

HY-N0864

Macranthoidin B Macranthoiside I	Apoptosis COX Reactive Oxygen Species (ROS) Caspase SOD	Cancer
Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels . Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma .

HY-124295

Imofinostat ABT-301; MPT0E028; TMU-C-0012	HDAC Akt Apoptosis	Inflammation/Immunology Cancer
Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC₅₀s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC₅₀ of 2.5 μM), but no inhibitory effect on HDAC4 (IC₅₀>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small cell lung carcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis .

HY-13653R

(-)-Epigallocatechin Gallate (Standard) Maximum Cited Publications 57 Publications Verification EGCG(Standard); Epigallocatechol Gallate (Standard)	Reference Standards Endogenous Metabolite Apoptosis	Inflammation/Immunology Cancer
(-)-Epigallocatechin Gallate (Standard) is the analytical standard of (-)-Epigallocatechin Gallate. This product is intended for research and analytical applications. (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-P99236

Bexmarilimab 1 Publications Verification FP-1305	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC₅₀ value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma .

HY-160215

GFH018	TGF-β Receptor p38 MAPK TGF-beta/Smad Interleukin Related	Cancer
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC₅₀ of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .

HY-P4193

AH1	MHC	Inflammation/Immunology Cancer
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8 ⁺ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I L ^d molecule. AH1 can be used for the research of colorectal carcinoma .

HY-P990033

Anzurstobart CC-95251; BMS-986351	CD47	Cancer
Anzurstobart is a CD47/SIRPα inhibitor with human SIRPα K_d of 0.0541 nM and human SIRPα IC₅₀ of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .

HY-N2445

Flavokawain C 4 Publications Verification	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK	Cancer
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-145396

PLGA12000-PEG2000-NH2	Biochemical Assay Reagents	Cancer
PLGA-PEG-NH2 is a material to synthesis nanomicelles. PLGA-PEG-NH2 nanomicelle is an efficient delivery system of Irinotecan for targeted colorectal cancer and hepatocellular carcinoma .

HY-153863

MS934	PROTACs MEK Raf	Cancer
MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC₅₀ values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .

HY-113041

Prostaglandin A2 PGA2; Medullin	Apoptosis Caspase PARP ERK MDM-2/p53 JNK HSV	Infection Cancer
Prostaglandin A2 (PGA2) is a Cyclopentenone prostaglandin. Prostaglandin A2 induces Caspase-dependent Apoptosis, activates p53. Prostaglandin A2 activates ERK2 and JNK1/SAPK. Prostaglandin A2 shows antiviral activity against HSV-1. Prostaglandin A2 has anti-tumor effects. Prostaglandin A2 can be used for the research of colorectal cancer, colorectal carcinoma, breast carcinoma, and herpetic keratitis .

HY-176761

NSC647889	Apoptosis Autophagy Caspase mTOR	Cancer
NSC647889 is an apoptosis and autophagy inducer. NSC647889 induces apoptosis, inhibits mTOR pathway and abrogates DNA synthesis. NSC647889 triggers LC3-positive vesicle formation, modulates AKT and 4EBP1 phosphorylation and shows heightened caspase-3 activation in multicellular spheroids. NSC647889 can be used for the research of solid cancer tumour, head-neck carcinoma, and colorectal cancer .

HY-P99406A

Petosemtamab (FUT8-KO)	EGFR	Cancer
Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .

HY-123901

Garcinone E	Apoptosis	Cancer
Garcinone E is a natural xanthone found in the rind of the mangosteen fruit. Garcinone E induces apoptosis and inhibits cancer cell migration. Garcinone E has anticancer effects on different human cancer cell lines, including colorectal, breast, and hepatocellular carcinomas .

HY-156529

pan-KRAS-IN-2	Ras	Cancer
pan-KRAS-IN-2 (Compound 6) is a pan-inhibitor with IC₅₀s ≤ 10 nM for KRAS WT and mutants (G12D, G12C, G12V, G12S, G12A and Q61H); and an IC₅₀ > 10 μM for KRAS G13D. pan-KRAS-IN-2 can be used to study various KRAS-mediated cancers, such as pancreatic cancer and colorectal cancer .

HY-150526

EGCG-4″-sulfate	Endogenous Metabolite Apoptosis	Inflammation/Immunology Cancer
EGCG-4″-sulfate is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate sulfate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. EGCG-4″-sulfate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-13653S1

(-)-Epigallocatechin Gallate-d4 EGCG-d₄; Epigallocatechol Gallate-d₄	Isotope-Labeled Compounds Apoptosis	Inflammation/Immunology Cancer
(-)-Epigallocatechin Gallate-d₄ (EGCG-d₄) is the deuterium labeled (-)-Epigallocatechin Gallate (HY-13653). (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-164712

E-Cadherin activator-1	Cadherin	Cancer
E-cadherin activator-1 (Compound 13m) is an E-Cadherin activator. E-cadherin activator-1 can be used in the study of colorectal carcinoma .

HY-114461B

(3S,17S)-FD-895	Drug Derivative DNA/RNA Synthesis	Cancer
(3S,17S)-FD-895 a FD-895 (HY-114461) analogue, is a spliceosome modulator. (3S,17S)-FD-895 inhibits cancer cell growth and exhibits gene-selective splice modulatory activity. (3S,17S)-FD-895 can be used for the research of colorectal carcinoma .

HY-136567

TBAP-001	Raf	Cancer
TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a pan-RAF kinase inhibitor, with an IC₅₀ of 62 nM in BRAF V600E kinase assay .

HY-108798

Ziv-aflibercept	VEGFR	Cardiovascular Disease Cancer
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .

HY-176861

Hakin-1	E1/E2/E3 Enzyme Cadherin	Cancer
Hakin-1 is a E3 Ubiquitin-Ligase Hakai inhibitor. Hakin-1 blocks Hakai-mediated global ubiquitination and specific ubiquitination of E-cadherin and inhibits epithelial-mesenchymal transition (EMT) progression. Hakan-1 inhibits tumor progression and cancer metastasis. Hakin-1 can be used for the study of carcinoma such as colorectal cancer .

HY-W008091S

5-Methylcytosine-d4	DNA/RNA Synthesis Endogenous Metabolite Isotope-Labeled Compounds	Cancer
5-Methylcytosine-d₄ is the deuterium labeled 5-Methylcytosine (HY-W008091). 5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma .

HY-110339

RKI-1447 dihydrochloride 4 Publications Verification	ROCK Apoptosis	Cancer
RKI 1447 dihydrochloride is a potent and selective ROCK inhibitor with IC₅₀s of 14.5 and 6.2 nM for ROCK1 and ROCK2, respectively . RKI 1447 dihydrochloride suppresses colorectal carcinoma cell growth and promotes apoptosis .

HY-175164

SVC112	Apoptosis c-Myc	Cancer
SVC112 is a translation elongation inhibitor that prevents the cyclic dissociation of EF2 from the ribosome, thereby inhibiting the elongation step of translation. SVC112 shows activity in growth inhibition among cancer cell lines of various origins (acute myeloid leukemia (AML), multiple myeloma (Myeloma), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC)). SVC112 preferentially impedes ribosomal processing of mRNAs, and decreaseds CSC-related proteins including Myc and Sox2. SVC112 induces apoptosis in hematologic cancer cell lines, while phosphorylation of c-Myc correlates with sensitivity to SVC112 in colorectal cancer cell lines. SVC112 inactivates HNSCC stem cells in vitro and prevents the regrowth of HNSCC tumor xenografts in mice. SVC112 can be used for the study of HNSCC .

HY-N7496

Odoroside A	Apoptosis	Cancer
Odoroside A is an active ingredient extracted from the leaves of Nerium oleander Linn. Odoroside A has anti-cancer activity. Odoroside A could induce apoptosis and cell cycle arrest through ROS/p53 signaling pathway, leading to the tumor cell death .

HY-153067

Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan (Compound 11) is a bioactive compound-linker conjugate for ADC. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can conjugate with antibodies to form ADC (C-11) with anti-tumor activity. Exatecan is a DNA Topoisomerase I inhibitor. Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan can be used in the research of squamous cell carcinoma, pancreatic adenocarcinoma and colorectal cancer .

HY-W008091R

5-Methylcytosine (Standard) 1 Publications Verification	Reference Standards DNA/RNA Synthesis Endogenous Metabolite	Cancer
5-Methylcytosine (Standard) is the analytical standard of 5-Methylcytosine (HY-W008091). This product is intended for research and analytical applications. 5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma .

HY-161871

WEE1-IN-8	Wee1	Cancer
WEE1-IN-8 (Compound 55) is a selective WEE1 inhibitor, with an IC₅₀ of 0.98 nM. WEE1-IN-8 (Compound 55) can be used for the research of Pancreatic cancer, Ovarian cancer, Colorectal cancer, Uterine serous carcinoma, etc .

HY-179336

TLR7/8 agonist 14	Toll-like Receptor (TLR) Interleukin Related IFNAR TNF Receptor	Cancer
TLR7/8 agonist 14 is a TLR7 and TLR8 agonist with EC₅₀ values of 0.53 μM and 4.3 μM, respectively. TLR7/8 agonist 14 increases the secretion of the proinflammatory cytokines TNF-α, IL-1β, IL-8 and IFN-γ. TLR7/8 agonist 14 increases cytokine secretion and expression of CD86. LR7/8 agonist 14 can be used for research colorectal carcinoma .

HY-129247

Versicolorin A	MDM-2/p53 Aryl Hydrocarbon Receptor Cytochrome P450	Cancer
Versicolorin A is a biosynthetic precursor of Aflatoxin B1 (HY-N6615). Versicolorin A induces phosphorylation of p53. Versicolorin A activates the aryl hydrocarbon receptor AhR and significantly induces the expression of CYP1A1. Versicolorin A exerts genotoxic and cytotoxic effects. Versicolorin A enhances the genotoxicity of aflatoxin B1 in cells by promoting CYP450-mediated bioactivation of aflatoxin B1. Versicolorin A can be used in research related to colorectal cancer and hepatocellular carcinoma .

HY-113264

PGD2 ethanolamide	Apoptosis	Cancer
PGD2 ethanolamide is the COX-2 dependent metabolite of Anandamide that induces apoptosis in colorectal carcinoma (CRC) cells .

HY-N1261

Scutebarbatine B	Others	Cancer
Scutebarbatine B shows significant cytotoxic activities against three human cancer lines, namely, HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma cells, with IC₅₀ values in the range 3.5-8.1 mM ^[1]<

HY-168620

CDK6-IN-1	CDK	Cancer
CDK6-IN-1 (compound 4i) is a CDK6 inhibitor. CDK6-IN-1 inhibits cell growth and induces cell cycle arrest at G1-phase .

HY-W008091A

5-Methylcytosine hydrochloride 2 Publications Verification	DNA/RNA Synthesis Endogenous Metabolite	Cancer
5-Methylcytosine hydrochloride is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine hydrochloride forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine hydrochloride can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine hydrochloride can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma .

HY-109015S

Tucidinostat-d4 Chidamide-d₄; HBI-8000-d₄; CS 055-d₄	Isotope-Labeled Compounds HDAC	Cancer
Tucidinostat-d₄ is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC₅₀s of 95, 160, 67 and 78 nM, respectively .

HY-P990275

Anti-Mouse CD326/EpCAM Antibody (G8.8)	Transmembrane Glycoprotein	Cancer
Anti-Mouse CD326/EpCAM Antibody (G8.8) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD326/EpCAM. Anti-Mouse CD326/EpCAM Antibody (G8.8) reacts with CD326 also known as EpCAM (Epithelial Cell Adhesion Molecule). Anti-Mouse CD326/EpCAM Antibody (G8.8) can be used for cancer research, such as lung carcinoma and colorectal carcinoma. Anti-Mouse CD326/EpCAM Antibody (G8.8) can be used for detections of western blot, immunohistochemistry, immunofluorescence and flow cytometry .

HY-W854385A

Sialyl Lewis A sodium 1 Publications Verification SLeA sodium	Biochemical Assay Reagents	Cancer
Sialyl Lewis A (SLeA) sodium is a tumor-associated carbohydrate antigen, also known as carbohydrate antigen 19-9 (CA19-9), that binds to E-selectin (ELAM-1) and selectins to mediate cell-endothelium adhesion. Sialyl Lewis A sodium promotes cancer cell-vascular endothelium adhesion, and its surface presence correlates with increased tumorigenicity and invasiveness in cancer cells. Sialyl Lewis A sodium shows elevated expression in human adenocarcinomas of the colon, pancreas, and stomach, with expression levels linked to tumor progression and poor prognosis in colorectal and gastric carcinomas. Sialyl Lewis A sodium can be used for the research of cancers, such as colon, pancreas, stomach, and squamous lung cancer .

HY-176534

PRMT5-IN-52	Histone Methyltransferase	Cancer
PRMT5-IN-52 (Compound 17) is a non-nucleoside Protein Arginine Methyltransferase 5 (PRMT5) inhibitor with inhibitory rates of 20.2% at 10 μM. PRMT5-IN-52 has potent antitumor activity, promising for research of cancers, including lung, prostate cancer, and colorectal carcinoma .

HY-160215A

GFH018 methylbenzenesulfonate	TGF-β Receptor p38 MAPK TGF-beta/Smad Interleukin Related	Cancer
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC₅₀ of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .

Cat. No.	Product Name	Type

HY-138794G

XL177A

Fluorescent Dyes

XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

HY-10966G

SB-590885

Fluorescent Dyes

SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

Cat. No.	Product Name	Type

HY-145396

PLGA12000-PEG2000-NH2	Biochemical Assay Reagents
PLGA-PEG-NH2 is a material to synthesis nanomicelles. PLGA-PEG-NH2 nanomicelle is an efficient delivery system of Irinotecan for targeted colorectal cancer and hepatocellular carcinoma .

HY-138794G

XL177A

Biochemical Assay Reagents

HY-10966G

SB-590885

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P4193

AH1	MHC	Inflammation/Immunology Cancer
AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8 ⁺ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I L ^d molecule. AH1 can be used for the research of colorectal carcinoma .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-P1654

A20FMDV2	Integrin	Cancer
A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC₅₀ values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .

HY-P1684

Peptide P60 1 Publications Verification FOXP3 inhibitor P60	NF-κB Nuclear Factor of activated T Cells (NFAT)	Infection Inflammation/Immunology Cancer
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 ⁺CD25 ⁺Foxp3 ⁺ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .

HY-P11060

MC38 SLP Adpgk Adpgk peptide	MHC	Cancer
MC38 SLP Adpgk (Adpgk peptide) is an H-2 K ^b-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice .

HY-P10765

DTS-108	Peptide-Drug Conjugates (PDCs) Topoisomerase	Cancer
DTS-108 is a prodrug of SN38 (HY-13704) (a Topoisomerase I inhibitor). DTS-108 is a conjugate generated by linking SN38 to a human oligopeptide via an esterase sensitive cross-linker. DTS-108 exhibits anti-tumor activity against colorectal, lung, and mammary cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P990957

Ficerafusp alfa BCA-101; FMAB2	EGFR TGF-beta/Smad	Inflammation/Immunology Cancer
Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a K_d of 2.58 nM against EGFR and a K_d of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatory T cells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .

HY-P99231

Edrecolomab Panorex; CO17-1A	Inhibitory Antibodies	Cancer
Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research .

HY-P99236

Bexmarilimab 1 Publications Verification FP-1305	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC₅₀ value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma .

HY-P990033

Anzurstobart CC-95251; BMS-986351	CD47	Cancer
Anzurstobart is a CD47/SIRPα inhibitor with human SIRPα K_d of 0.0541 nM and human SIRPα IC₅₀ of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .

HY-P991526

M701	CD3	Cancer
M701 is a T-cell engager bispecific humanized antibody targeting epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). M701 binds to EpCAM on tumor cells and CD3 on T cells, thereby linking the two cell populations to achieve targeted cytotoxicity and T cell-mediated cytotoxicity. M701 is applicable to research related to advanced epithelial solid tumors .

HY-P99406A

Petosemtamab (FUT8-KO)	EGFR	Cancer
Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .

HY-P991196

Anti-CD24 Antibody (SWA11)	Transmembrane Glycoprotein	Cancer
Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody (mAb) targeting CD24, with high affinity and specificity for tumor cells expressing CD24. Anti-CD24 Antibody (SWA11) binds to CD24 on tumor cells, triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) exhibits anticancer effects, such as against lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-108798

Ziv-aflibercept	VEGFR	Cardiovascular Disease Cancer
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .

HY-P991248

TTX-080	Inhibitory Antibodies	Cancer
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G). TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) .

HY-P990275

Anti-Mouse CD326/EpCAM Antibody (G8.8)	Transmembrane Glycoprotein	Cancer
Anti-Mouse CD326/EpCAM Antibody (G8.8) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD326/EpCAM. Anti-Mouse CD326/EpCAM Antibody (G8.8) reacts with CD326 also known as EpCAM (Epithelial Cell Adhesion Molecule). Anti-Mouse CD326/EpCAM Antibody (G8.8) can be used for cancer research, such as lung carcinoma and colorectal carcinoma. Anti-Mouse CD326/EpCAM Antibody (G8.8) can be used for detections of western blot, immunohistochemistry, immunofluorescence and flow cytometry .

HY-P991244

REGN-1400	EGFR	Cancer
REGN-1400 is a humanized monoclonal antibody inhibitor targeting ErbB3. REGN-1400 reduces tumor cell proliferation by inhibiting ErbB3 and blocking related signaling pathways. REGN-1400 is promising for research of solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and squamous cell carcinoma of the head and neck (SCCHN) .

HY-P99881

Rolinsatamab talirine ABBV 176	Antibody-Drug Conjugates (ADCs)	Cancer
Rolinsatamab talirine (ABBV 176) is a prolactin receptor (PRLR)-targeting antibody-drug conjugate (ADC), compoused of Rolinsatamab (HY-P99238) and SGD-1882 (HY-101127). Rolinsatamab talirine binds to PRLR to deliver a cytotoxin to tumor cells. Rolinsatamab talirine induces DNA damage, and exhibits cytotoxicity against multiple breast tumor models, including triple negative and low PRLR-expressing models. Rolinsatamab talirine demonstrates enhanced anti-tumor activity in several breast cancer models. Rolinsatamab talirine can be used for the research of breast cancer, hepatocellular carcinoma, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, adrenocortical carcinoma, and solid tumors .

HY-P991968

HTI-1511 Antibody Halozyme patent anti-EGFR	EGFR	Cancer
HTI-1511 Antibody (Halozyme patent anti-EGFR) is a monoclonal antibody inhibitor targeting EGFR. HTI-1511 Antibody can be used to synthesize a novel anti-EGFR-ADC, HTI-1511. HTI-1511 Antibody can be used in the research of head and neck squamous cell carcinoma, non-small cell lung cancer, pancreatic cancer, colorectal cancer, renal cell carcinoma, and epidermoid carcinoma .

HY-P991969

LR004	EGFR	Cancer
LR004 is an EGFR monoclonal antibody, with a K_d of 2.80×10 ^-9 M against human EGFR. LR004 shows extremely weak inhibitory effect on the viability of EGFR-positive tumor cells in vitro, but inhibits the growth of EGFR-positive tumor xenografts as a single agent. LR004 is applicable to research related to advanced colorectal cancer, solid tumors, esophageal squamous cell carcinoma, epidermoid carcinoma, colon cancer and breast cancer .

HY-P991911

PLT012	Scavenger Receptor Class B type I (SR-BI）	Cancer
PLT012 is a humanized IgG4 antibody targeting CD36. PLT012 inhibits the lipid-binding domain of CD36. PLT012 blocks CD36-mediated metabolic adaptation in regulatory T cells (Tregs) and CD8 ⁺ tumor-infiltrating lymphocytes (TILs), thereby inhibiting tumor growth and shifting the tumor microenvironment from immunosuppressive to immunosupportive. PLT012 reduces intratumoral Tregs, enhances CD8 ⁺ T cell infiltration and cytotoxic function, and increases the abundance of progenitor-exhausted T cells. PLT012 exerts robust antitumor activity and synergizes with anti-PD-L1 or standard-of-care regimens (anti-VEGF + anti-PD-L1). PLT012 can be used for hepatocellular carcinoma, colorectal cancer and solid tumor research .

HY-P992361

HB0030	Transmembrane Glycoprotein	Cancer
HB0030 is a TIGIT inhibitor with antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. HB0030 enhances the expression of activation markers in natural killer (NK) cells, promotes the killing of regulatory T cells (Tregs), and reduces the proportion of FoxP3 ⁺ Treg in tumor-infiltrating lymphocytes. The combination of HB0030 with the anti-PD-L1/VEGF bispecific antibody HB0025 further enhances tumor suppression efficacy. HB0030 can be used in studies related to colorectal cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, bladder cancer, breast cancer, non-small cell lung cancer, and advanced solid tumors .

HY-P992360

GT-002	GABA Receptor	Neurological Disease Cancer
GT-002 is a partial positive allosteric modulator targeting the α3 subtype of GABAA receptors, as well as a specific binder of tumor-associated TF-glycosylated LYPD3. GT-002 mildly enhances GABA-induced chloride currents by binding to the benzodiazepine site of GABAA receptors, thereby alleviating prefrontal hypofunction and improving cognitive, memory and social interaction abilities. GT-002 can be used in research related to schizophrenia spectrum disorders, various squamous cell carcinomas, colorectal cancer, non-small cell lung cancer, and aromatic L-amino acid decarboxylase deficiency .

HY-P992365

HFB101110	CCR	Cancer
HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .

HY-P992373

huCC49	Mucin	Cancer
huCC49 is a human monoclonal antibody targeting TAG-72. huCC49 can be used in cancer-related research. The recommended isotype control is human IgG1 kappa, with the isotype control (HY-P99001) .

HY-P992395

JNJ-64164711 JNJ-711	TNF Receptor NF-κB	Cancer
JNJ-64164711 (JNJ-711) is a bifunctional antibody that simultaneously targets human GITR/TNFRSF18 and FcγRIIIa. JNJ-64164711 binds to the GITR domain to activate the NF-κB signaling pathway, while binding to FcγRIIIa to support antibody-dependent cellular cytotoxicity (ADCC). JNJ-64164711 can specifically eliminate GITR-positive hematological tumor cells, activated T cells and intratumoral regulatory T cells through the ADCC mechanism, thereby significantly enhancing the body's anti-tumor immune response. JNJ-64164711 can be used in research related to non-small cell lung cancer, colorectal cancer, prostate cancer, renal cell carcinoma and hematological tumors .

HY-P992450

REGN6569	TNF Receptor	Cancer
REGN6569 is a fully human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatory T cells expressing GITR. REGN6569 selectively depletes regulatory T cells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13653

(-)-Epigallocatechin Gallate Maximum Cited Publications 57 Publications Verification EGCG; Epigallocatechol Gallate	Structural Classification Classification of Application Fields Anti-aging Plants Endogenous metabolite Flavonoids other families Flavonones Phenols Polyphenols Inflammation/Immunology Disease Research Fields Source Classification Cancer	Endogenous Metabolite Apoptosis
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-W008091

5-Methylcytosine 2 Publications Verification	Natural Products Microorganisms Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	DNA/RNA Synthesis Endogenous Metabolite
5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma .

HY-N0864

Macranthoidin B Macranthoiside I	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	Apoptosis COX Reactive Oxygen Species (ROS) Caspase SOD
Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels . Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma .

HY-13653R

(-)-Epigallocatechin Gallate (Standard) Maximum Cited Publications 57 Publications Verification EGCG(Standard); Epigallocatechol Gallate (Standard)	Flavonoids other families Classification of Application Fields Anti-aging Phenols Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification Cancer	Reference Standards Endogenous Metabolite Apoptosis
(-)-Epigallocatechin Gallate (Standard) is the analytical standard of (-)-Epigallocatechin Gallate. This product is intended for research and analytical applications. (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-N2445

Flavokawain C 4 Publications Verification	Structural Classification Classification of Application Fields Piperaceae Plants Chalcones Flavonoids other families Phenols Polyphenols Piper methysticum G.Forst. Disease Research Fields Source Classification Cancer	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-N5112A

β,β-Dimethylacrylalkannin 3 Publications Verification Arnebin 1	Quinones Structural Classification other families Classification of Application Fields Other Diseases Plants Naphthalene Quinones Pteris livida Mett. Disease Research Fields	FGFR Necroptosis Apoptosis CDK JNK
β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active FGFR1 inhibitor (IC₅₀=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the CDK1/Cdc25C pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis .

HY-114988

PGE-M tetranor-PGEM	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification Cancer	Drug Metabolite
PGE-M (tetranor-PGEM) is a metabolite of Prostaglandin E₂ (HY-101952) and also an inflammatory biomarker. Urinary PGE-M is a potential biomarker for detecting advanced colorectal tumors. PGE-M can be used in studies related to colorectal cancer, obesity, aging and breast cancer .

HY-17026A

Gemcitabine triphosphate dFdCTP	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite DNA/RNA Synthesis Apoptosis
Gemcitabine triphosphate (dFdCTP) is the active metabolite of Gemcitabine (HY-17026). The mechanism of Gemcitabine triphosphate cell-killing is its competition with cytidine triphosphate during DNA replication, which results in the inhibition of chain elongation. Gemcitabine triphosphate shows a K_i of 11.2 μM against DNA polymerase α and 14.4 μM against DNA polymerase ε. Gemcitabine triphosphate partially inhibits dCMP deaminase and acts as a substrate for DNA synthesis to incorporate into cellular DNA and RNA. Gemcitabine triphosphate disrupts DNA and RNA synthesis, arrests cell cycle in G0/G1 and S phases, triggers apoptosis, reduces tumor cell proliferation. Gemcitabine triphosphate can be used for the research of pancreatic cancer and non-small cell lung cancer .

HY-N0093

Ancitabine hydrochloride 1 Publications Verification Cyclocytidine hydrochloride; Cyclo-CMP hydrochloride; Cyclo-C	Classification of Application Fields Disease Research Fields Cancer	Autophagy CMV DNA/RNA Synthesis
Ancitabine hydrochloride is a cytarabine derivative that inhibits viral replication. Ancitabine hydrochloride blocks vaccinia virus DNA replication, the progression of viral protein synthesis from early to late stages, and one-step growth of vaccinia virus. Ancitabine hydrochloride is applicable to research related to vaccinia virus infection, leukemia, human cytomegalovirus infection and colorectal cancer .

HY-N0566

23-Hydroxybetulinic acid Anemosapogenin	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	Apoptosis Autophagy Bcl-2 Family Caspase Survivin p38 MAPK MMP
23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer .

HY-123901

Garcinone E	Flavonoids Guttiferae Garcinia mangostana Linn. Plants Other Flavonoids Source Classification	Apoptosis
Garcinone E is a natural xanthone found in the rind of the mangosteen fruit. Garcinone E induces apoptosis and inhibits cancer cell migration. Garcinone E has anticancer effects on different human cancer cell lines, including colorectal, breast, and hepatocellular carcinomas .

HY-150526

EGCG-4″-sulfate	Flavonoids Classification of Application Fields Flavanols Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification Cancer	Endogenous Metabolite Apoptosis
EGCG-4″-sulfate is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate sulfate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. EGCG-4″-sulfate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-N7496

Odoroside A	Apocynaceae Structural Classification Classification of Application Fields Nerium oleander Plants Disease Research Fields Steroids Cancer	Apoptosis
Odoroside A is an active ingredient extracted from the leaves of Nerium oleander Linn. Odoroside A has anti-cancer activity. Odoroside A could induce apoptosis and cell cycle arrest through ROS/p53 signaling pathway, leading to the tumor cell death .

HY-W008091R

5-Methylcytosine (Standard) 1 Publications Verification	Structural Classification Natural Products Microorganisms Endogenous metabolite Source Classification	Reference Standards DNA/RNA Synthesis Endogenous Metabolite
5-Methylcytosine (Standard) is the analytical standard of 5-Methylcytosine (HY-W008091). This product is intended for research and analytical applications. 5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma .

HY-129247

Versicolorin A	Quinones Structural Classification Microorganisms Classification of Application Fields Anthraquinones Other Diseases Disease Research Fields Source Classification	MDM-2/p53 Aryl Hydrocarbon Receptor Cytochrome P450
Versicolorin A is a biosynthetic precursor of Aflatoxin B1 (HY-N6615). Versicolorin A induces phosphorylation of p53. Versicolorin A activates the aryl hydrocarbon receptor AhR and significantly induces the expression of CYP1A1. Versicolorin A exerts genotoxic and cytotoxic effects. Versicolorin A enhances the genotoxicity of aflatoxin B1 in cells by promoting CYP450-mediated bioactivation of aflatoxin B1. Versicolorin A can be used in research related to colorectal cancer and hepatocellular carcinoma .

HY-N1261

Scutebarbatine B	Alkaloids Classification of Application Fields Labiatae Derris robusta Pyridine Alkaloids Plants Disease Research Fields Cancer Source Classification	Others
Scutebarbatine B shows significant cytotoxic activities against three human cancer lines, namely, HONE-1 nasopharyngeal, KB oral epidermoid carcinoma, and HT29 colorectal carcinoma cells, with IC₅₀ values in the range 3.5-8.1 mM ^[1]<

HY-N144114

P-gp inhibitor 2	Classification of Application Fields Disease Research Fields Cancer	P-glycoprotein
P-gp inhibitor 2 is a potent P-gp inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC₅₀=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .

HY-N0864R

Macranthoidin B (Standard) Macranthoiside I (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards Others
Macranthoidin B (Macranthoiside I) Standard is the analytical standard of Macranthoidin B (HY-N0864). This product is intended for research and analytical applications. Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels . Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma .

HY-N0566R

23-Hydroxybetulinic acid (Standard) Anemosapogenin (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards Apoptosis Autophagy Bcl-2 Family Caspase Survivin p38 MAPK MMP
23-Hydroxybetulinic acid (Standard) is the analytical standard of 23-Hydroxybetulinic acid (HY-N0566). This product is intended for research and analytical applications. 23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer.

HY-N19311

3,6-Bis(1-methylpropyl)-2(1H)-pyrazinone	Structural Classification Alkaloids Microorganisms Other Alkaloids Source Classification	Bacterial
3,6-Bis(1-methylpropyl)-2(1H)-pyrazinone is an alkylated 2(1H)-pyrazinone derivative and cytotoxic agent found in the tunicate-derived actinomycete Streptomyces sp. Did-27.3,6-Bis(1-methylpropyl)-2(1H)-pyrazinone exhibits cytotoxic activity against cancer cells.3,6-Bis(1-methylpropyl)-2(1H)-pyrazinone can be used for the research of colorectal carcinoma, hepatocellular carcinoma, breast cancer .

HY-N19818

Glycybridin C	Structural Classification Glycyrrhiza glabra Linn. Leguminosae Phenols Polyphenols Plants Source Classification	Phosphatase NF-κB Pregnane X Receptor (PXR)
Glycybridin C is a Protein tyrosine phosphatase 1B (PTP1B) inhibitor and pregnane X receptor (PXR) ligand. Glycybridin C inhibits insulin and leptin signaling pathway negative regulation, LPS (HY-D1056)-induced NF-κB transcriptional activity. Glycybridin C forms hydrophobic and π-π stacking interactions with Met243, Phe288, Tyr306, and His407 residues of PXR. Glycybridin C can be used for the research of hepatocellular carcinoma, colorectal adenocarcinoma, breast carcinoma .

HY-N18272

1α-Benzoyloxy-3α-acetoxyl-7α-hydroxy-12β-ethoxynimbolinin	Structural Classification Natural Products Melia azedarach Linn. Plants Meliaceae Source Classification	Others
1α-Benzoyloxy-3α-acetoxyl-7α-hydroxy-12β-ethoxynimbolinin is a nimbolinin-type limonoid and cytotoxin, found in the fruits of Melia toosendan. 1α-Benzoyloxy-3α-acetoxyl-7α-hydroxy-12β-ethoxynimbolinin exhibits in vitro cytotoxicity against human hepatocellular carcinoma, human lung cancer, and human breast cancer cells. 1α-Benzoyloxy-3α-acetoxyl-7α-hydroxy-12β-ethoxynimbolinin can be used for the research of hepatocellular carcinoma, lung cancer, breast cancer .

HY-N18339

Camaroside	Apocynaceae Structural Classification Flavonoids Flavones Calotropis procera (Aiton) W. T. Aiton Plants Source Classification	Drug Derivative
Camaroside is a flavonoid glycoside with weak cytotoxic activity against cancer cells and fibroblasts, and no significant antimicrobial activity. Camaroside reduces metabolic activity of fibroblasts and liver cancer cells.C amaroside can be found in the vegetative stems of Calotropis procera .

HY-W697750

trans-2-Methyl-2-butenal Tiglaldehyde	Structural Classification Natural Products Allium schoenoprasum L. Plants Amaryllidaceae Source Classification	Biochemical Assay Reagents
trans-2-Methyl-2-butenal (Tiglaldehyde) is an adduct former that can be found in cigarette smoke, and very weakly inhibits growth of cancer cells and normal mouse cells. trans-2-Methyl-2-butenal forms adducts with glutathione (GSH) via Michael addition.trans-2-Methyl-2-butenal is an α,β-unsaturated carbonyl compound .

Cat. No.	Product Name	Chemical Structure

HY-13653S1

(-)-Epigallocatechin Gallate-d4

(-)-Epigallocatechin Gallate-d₄ (EGCG-d₄) is the deuterium labeled (-)-Epigallocatechin Gallate (HY-13653). (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

HY-W008091S

5-Methylcytosine-d4

5-Methylcytosine-d₄ is the deuterium labeled 5-Methylcytosine (HY-W008091). 5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma .

HY-109015S

Tucidinostat-d4
Tucidinostat-d₄ is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC₅₀s of 95, 160, 67 and 78 nM, respectively .

HY-170017S

(−)-Epigallocatechin Gallate-d3/d4

(-)-Epigallocatechin Gallate-d₃/d₄ (EGCG-d₃/d₄) is the deuterium labeled (-)-Epigallocatechin Gallate (HY-13653). (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma .

Cat. No.	Product Name		Classification

HY-145396

PLGA12000-PEG2000-NH2		Polymers
PLGA-PEG-NH2 is a material to synthesis nanomicelles. PLGA-PEG-NH2 nanomicelle is an efficient delivery system of Irinotecan for targeted colorectal cancer and hepatocellular carcinoma .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138794G

XL177A	Deubiquitinase SARS-CoV Histone Demethylase	Cancer
XL177A GMP is XL177A (HY-138794) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .

HY-10966G

SB-590885	Raf Apoptosis	Cardiovascular Disease Cancer
SB-590885 GMP is SB-590885 (HY-10966) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Colorectal carcinomas

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Natural
Products